[go: up one dir, main page]

EP1351976A2 - Analogues de gpe - Google Patents

Analogues de gpe

Info

Publication number
EP1351976A2
EP1351976A2 EP01968959A EP01968959A EP1351976A2 EP 1351976 A2 EP1351976 A2 EP 1351976A2 EP 01968959 A EP01968959 A EP 01968959A EP 01968959 A EP01968959 A EP 01968959A EP 1351976 A2 EP1351976 A2 EP 1351976A2
Authority
EP
European Patent Office
Prior art keywords
gpe
pharmaceutical composition
analog
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01968959A
Other languages
German (de)
English (en)
Inventor
Peter Gluckman
Tajrena Alexi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuronz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd filed Critical Neuronz Ltd
Publication of EP1351976A2 publication Critical patent/EP1351976A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to GPE analogs.
  • GPE is a tri-peptide consisting of amino acids Gly-Pro-Glu. It and its di-peptide derivatives Gly-Pro and Pro-Glu were first disclosed by Sara et al in EP 0366638. Sara et al disclosed that GPE is effective as a neuromodulator (able to affect the electrical properties of neurons).
  • GPE has neuroprotective properties and that it therefore has utility in the prevention or inhibition of neural cell death (WO 95/17204).
  • the nervous system contains neural cells and glial cells.
  • Glial cells including astrocytes, microglia, Schwann cells in the peripheral nervous system and oligodendrocytes in the central nervous system, often aid neural cells and neural activity by providing support and assistance to neural cells through means including anatomical configuration, metabolic activity, and physiological function.
  • GPE analogs have application on an equivalent basis to GPE, including in treating and/or preventing neural damage following insult.
  • the present invention provides a molecule which: (i) has a neural binding-site profile which is at least substantially equivalent to GPE; and (ii) which has a neural bioactivity profile which is at least substantially equivalent to that of GPE,
  • said molecule being other than GPE or its di-peptide derivatives Gly-Pro and Pro- Glu.
  • the molecule also has an ability to cross the blood brain barrier in humans which is at least substantially equivalent to GPE.
  • compositions particularly those adapted for peripheral or intrathecal administration to a human patient, which comprise a molecule as defined above.
  • the invention provides a method of inducing a neuroprotective effect in a patient for therapy and/or prophylaxis which comprises the step of administering a molecules and/or a pharmaceutical composition as defined above to said patient.
  • Figure 1 shows the binding site distribution of H-Me-GPE in the rat brain
  • Figure 2 shows the binding site distribution of 3 H-Me-GPE in the human brain
  • Figure 3 is a graph showing accumulation of tritiated GPE in the brain over time
  • Figure 4 shows the effect of GPE administered peripherally on neuronal survival after an hypoxic-ischemic injury.
  • the invention is broadly directed to molecules which are GPE analogs. Such molecules will normally be structurally related to GPE and will in each case be capable of inducing an equivalent physiological effect to GPE within a patient.
  • a protein can be considered a functional equivalent of another protein for a specific function if the equivalent protein is immunologically cross-reactive with the original protein.
  • the equivalent can be, for example, a fragment of a protein, a fusion of the protein with another protein or carrier, or a fusion of a fragment with additional amino acids.
  • GPE is the tripeptide Gly-Pro-Glu
  • GPE analogs include substitutions where the Gly of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Pro; where the Pro of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Gly; and where the Glu of Gly-Pro-Glu is replaced by any of Asn, Asp, or Gin. All of these equivalent molecules constitute GPE analogs of the invention.
  • the probability of one amino acid sequence being functionally equivalent to another can be measured by the computer algorithm BLASTP (Altschul et al 1990 J. Mol. Biol. 215: 403-410).
  • GPE amides and stearates. More particularly, specific analogs include the following:
  • GPE having a neural binding-site profile which is at least substantially equivalent to GPE having a neural bioactivity profile which is at least substantially equivalent to GPE - and desirably, although not essentially, having an ability to cross the blood brain barrier (including in the absence of neural insult) which is at least substantially equivalent to GPE.
  • the neural binding-site profile for GPE has been determined as per Experiment 1 and is shown in Figures 1 and 2.
  • the ability of a candidate GPE analog to cross the blood brain barrier can be determined, and compared to passage rates for GPE, by following the procedures as set out in Experiment 2.
  • the accumulation of the candidate analog can be measured 60 minutes following cardiac administration for ready comparison with GPE.
  • the neural bioactivity profile of a candidate GPE analog can be determined, and compared to that of GPE, by following the procedures set out in Experiment 3.
  • GPE analogs can reduce neuronal cell loss due to damage caused by an insult.
  • An insult is damage, injury or stress that may lead to death or dysfunction of nervous or glial cells or tissues.
  • GPE analogs have application in any method of therapy or prophylaxis in which GPE has application. These include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS.
  • GPE analogs may be used in the treatment of multiple sclerosis. Such treatment may be acute (e.g., mainly directed to treating present symptoms) or may be chronic (e.g., mainly directed towards curing the disease, or towards preventing progression of the disease and long-term amelioration of symptoms).
  • a protective effect due to administration of a GPE analog prior to the insult is termed a prophylactic effect
  • a protective effect due to administration of a GPE analog during or after the insult is termed a resuscitative effect.
  • the protective effects of GPE analogs may be due to actions of GPE analogs on the neural cells themselves, on glial cells, or on cells of both types.
  • GPE analogs can be used in the manufacture of medicaments or pharmaceutical preparations for the treatment of medical conditions, including medical conditions resulting from neural injury or disease.
  • GPE analogs can be administered as part of a medicament or pharmaceutical preparation. This can involve combining GPE analogs with any pharmaceutically appropriate carrier, adjuvant or excipient. The selection of the carrier, adjuvant or excipient will of course usually be dependent upon the route of administration to be employed.
  • GPE analogs may be administered in different ways, including subcutaneously, intraperitoneally, intravenously and intracerebroventricularly. GPE analogs may be administered directly to a site of injury or of possible injury; for example, directly into the parenchyma of the brain or spinal cord. This can be achieved by any appropriate direct administration route. Examples of suitable methods include administration by lateral cerebroventricular injection or through a surgically inserted shunt into the lateral cerebroventricle of the brain of the patient.
  • GPE analogs may be administered to a location near to a site of injury or of possible injury; or to a body cavity in contact or fluid communication with a site of injury or of possible injury (such as, e.g., a cerebral ventricle or to the cerebrospinal fluid bathing the spinal cord).
  • the ability of the GPE analogs to cross the blood brain barrier allows them to be administered peripherally to a patient in need of treatment in the brain.
  • the peripheral application may be the way of choice because then there is no direct interference with the central nervous system.
  • Any peripheral route of administration known in the art can be employed. These can include parenteral routes for example injection into the peripheral circulation, subcutaneous, intraorbital, ophthalmic, intraspinal, intracisternal, topical, infusion (using eg. slow release devices or minipumps such as osmotic pumps or skin patches), implant, aerosol, inhalation, scarification, intraperitoneal, intracapsular, intramuscular, intranasal, oral, buccal, pulmonary, rectal or vaginal.
  • the compositions can be formulated for parenteral administration to humans or other mammals in therapeutically effective amounts (eg. amounts which eliminate or reduce the patient's pathological condition) to provide therapy for the neurological diseases described above.
  • Two of the most convenient administration routes include subcutaneous injection (e.g., dissolved in 0.9% sodium chloride) and oral adminstration (e.g., in a capsule).
  • GPE analogs may be administered before or after an insult leading to neural injury or neural damage has occurred, or may be administered concurrently with such an insult.
  • GPE analogs may be administered to a patient before a procedure or treatment which carries risk of neural damage in order to reduce or prevent any possible neural injury as result of the procedure or treatment.
  • GPE analogs may also be administered at any time up to and including about 100 hours after an insult to protect neural or glial cells from injury or death.
  • GPE analogs may be particularly effective when administered during a time period including the time between about 0.5 hours to about 8 hours after an insult to protect neural cells from injury or death.
  • a suitable dose range may for example be between about 0.01 mg to about 1 mg/100 g of body weight, or more specifically about 0.06 ⁇ g to 0.6 mg of GPE analog per 100 g of body weight where the dose is administered centrally.
  • GPE analogs can be directly synthesized by conventional methods such as the stepwise solid phase synthesis method of Merryfield et al, 1963 (J. Am. Chem. Soc. 15:2149-2154). Such methods of peptide synthesis are known in the art, and are described, e.g., in Fields and Colowick, 1997, Solid Phase Peptide Synthesis (Methods in Enzymology, vol. 289), Academic Press, San Diego, CA. Alternatively synthesis can involve the use of commercially available peptide synthesizers such as the Applied Biosystems model 430 A.
  • the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St.Louis, Mo.), or are prepared by methods well known to the person of ordinary skill in the art following procedures described in such references as Fieser and Fieser's Reagents for Organic Synthesis, vols 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supplements, Elsevier Science Publishers, 1989; Organic Reactions, vols.
  • Analogs of GPE, or modifications thereof, such as esters or amides may in general be prepared by methods such as are already well-known to persons of ordinary skill in the art of peptide and modified peptide synthesis by following other methods well-known to those of ordinary skill in the art of the synthesis of peptides and analogs.
  • synthetic production of the polypeptide of the invention may be according to the solid phase synthetic method described by Merrifield et al. Solid phase peptide synthesis.
  • the solid phase method of synthesis involves the stepwise addition of protected amino acids to a growing peptide chain which is bound by covalent bonds to a solid resin particle.
  • reagents and by-products are removed by filtration, thus eliminating the necessity of purifying intermediates.
  • the general concept of this method depends on attachment of the first amino acid of the chain to a solid polymer by a covalent bond. Succeeding protected amino acids are added, one at a time (stepwise strategy), or in blocks (segment strategy), until the desired sequence is assembled. Finally, the protected peptide is removed from the solid resin support and the protecting groups are cleaved off.
  • the amino acids may be attached to any suitable polymer as a resin.
  • the resin must contain a functional group to which the first protected amino acid can be firmly linked by a covalent bond.
  • Various polymers are suitable for this purpose, such as cellulose, polyvinyl alcohol, polymethylmethacrylate, and polystyrene. Suitable resins are commercially available and well known to those of skill in the art.
  • protective groups usable in such synthesis include tert-butyloxycarbonyl (BOC), benzyl (Bzl), t-amyloxycarbonyl (Aoc), tosyl (Tos), o-bromo-phenylmethoxycarbonyl (BrZ), 2,6-dichlorobenzyl (BzlCl 2 ), and phenylmethoxycarbonyl (Z or CBZ). Additional protective groups are identified in Merrifield, cited above, as well as in McOmie JFW: Protective Groups in Organic Chemistry, Plenum Press, New York, 1973.
  • the general procedure of preparation of the peptides of this invention involves initially attaching the protected carboxyl-terminal amino acid to the resin. After attachment the resin is filtered, washed and the protecting group (desirably BOC) on the ⁇ -amino group of the carboxyl-terminal amino acid is removed. The removal of this protecting group must take place, of course, without breaking the bond between that amino acid and the resin. The next amino, and if necessary, side chain protected amino acid, is then coupled to the free ⁇ -amino group of the amino acid on the resin. This coupling takes place by the formation of an amide bond between the free carboxyl group of the second amino acid and the amino group of the first amino acid attached to the resin.
  • the protecting group desirably BOC
  • peptide synthesis is described in Bodanszky et al, Peptide Synthesis, 2nd ed, John Wiley and Sons, New York, 1976.
  • the peptides of the invention may also be synthesized using standard solution peptide synthesis methodologies, involving either stepwise or block coupling of amino acids or peptide fragments using chemical or enzymatic methods of amide bond formation.
  • standard solution peptide synthesis methodologies involving either stepwise or block coupling of amino acids or peptide fragments using chemical or enzymatic methods of amide bond formation.
  • These solution synthesis methods are well known in the art.
  • analogs in which the glycine residue of GPE is replaced by an alternative amino acid may conveniently be prepared by the preparation of a protected proline-glutamic acid di-peptide (such as the dibenzyl ester)-, and coupling that dipeptide with a protected glycine analog, followed by deprotection.
  • analogs in which the glutamic acid residue of GPE is replaced by an alternative amino acid or an amino acid amide or ester may conveniently be prepared by the preparation of a protected glycine-L-proline di-peptide (such as BOC-glycyl-L- proline), and coupling that dipeptide with a protected glutamic acid and esters or glutamine.
  • Conjugation and modification of the resulting peptides may be accomplished by standard techniques known in the art. For example, esterification may be used to provide GPE-stearate, and amidation may be used to provide GPE-amide.
  • GPE analogs may be made by conjugating another molecule to GPE. For example, it is known in the art to conjugate polyethylene glycol (PEG) to peptides; such modified peptides are termed PEGylated peptides.
  • PEGylated GPE peptides comprise GPE analogs of the invention, and may be provided using, e.g., the conjugate technology described in WO 95/32003 published November 30, 1995.
  • Various weights of PEG may be used to provide a variety of PEGylated peptide analogs. PEGylated peptides often remain available within a patient for longer times than nonPEGylated peptides.
  • the total pharmaceutically effective amount of GPE analog administered parenterally per dose will be in a range that can be measured by a dose response curve.
  • the preferred range will be between about 0.01 mg to about 1 mg per 100 g body weight, specifically between about 0.06 mg/100 g body weight to about 0.6 mg/100 g body weight.
  • GPE analogs in the blood can be measured in body fluids of the mammal to be treated to determine dosing.
  • one can administer increasing amounts of the GPE analog to the patient and check the serum levels of the patient for the GPE analog.
  • the amount of GPE analog to be employed can be calculated on a molar basis based on these serum levels of GPE analog.
  • one method for determining appropriate dosing of the analog entails measuring GPE analog levels in a biological fluid such as a body or blood fluid. Measuring such levels can be done by any means, including RIA and ELISA. After measuring GPE analog levels, the fluid is contacted with the compound using single or multiple doses. After this contacting step, the GPE analog levels are re-measured in the fluid. If the fluid GPE analog levels have fallen by an amount sufficient to produce the desired efficacy for which the molecule is to be administered, then the dose of the molecule can be adjusted to produce maximal efficacy.
  • This method can be carried out in vitro or in vivo. Preferably, this method is carried out in vivo, i.e.
  • the analog herein is administered to the mammal using single or multiple doses (that is, the contacting step is achieved by administration to a mammal) and then the GPE analog levels are remeasured from fluid extracted from the mammal.
  • GPE analogs may also be suitably administered by a sustained-release system.
  • sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
  • Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919; EP 58,481), poly(2-hydroxyethyl methacrylate) (Langer et al, 1981), ethylene vinyl acetate (Langer et al, supra), or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
  • Sustained-release compositions also include a liposomally entrapped compound.
  • Liposomes containing GPE analogs are prepared by methods known per se: DE 3,218,121; Hwang et al, 1980; EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appln. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324.
  • the liposomes are of the small (from or about 200 to 800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol percent cholesterol, the selected proportion being adjusted for the most efficacious therapy. All documents referred to herein, both supra and infra, are hereby incorporated by reference in their entirety.
  • doses may be between about 0.01 to about 1 mg of GPE analog per 100 g of body weight, more specifically about 0.06 ⁇ g to 0.6 mg of GPE analog per lOOg body weight.
  • the analog is formulated generally by mixing each at the desired degree of purity, in a unit dosage mjectable form (solution, suspension, or emulsion), with a pharmaceutically, or parenterally, acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
  • the formulations are prepared by contacting the compound uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
  • the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, a buffered solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein.
  • the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
  • additives such as substances that enhance isotonicity and chemical stability.
  • Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycine; amino acids such as glutamic acid, aspartic acid, histidine, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, trehalose, or dextrins; chelating agents such as EDTA; sugar alcohols such as
  • the GPE analog is typically formulated in such vehicles at a pH of from or about 4.5 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of salts of the compound.
  • the final preparation may be a stable liquid or lyophilized solid.
  • Typical adjuvants which may be incorporated into tablets, capsules, and the like are a binder such as acacia, corn starch, or gelatin; an excipient such as microcrystalline cellulose; a disintegrating agent like corn starch or alginic acid; a lubricant such as magnesium stearate; a sweetening agent such as sucrose or lactose; a flavoring agent such as peppermint, wintergreen, or cherry.
  • the dosage form When the dosage form is a capsule, in addition to the above materials, it may also contain a liquid carrier such as a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit.
  • a syrup or elixir may contain the active compound, a sweetener such as sucrose, preservatives like propyl paraben, a coloring agent, and a flavoring agent such as cherry.
  • Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like may be desired. Buffers, preservatives, antioxidants, and the like can be incorporated according to accepted pharmaceutical practice.
  • the GPE analog to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
  • Therapeutic compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • the GPE analog ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
  • a lyophilized formulation 10 mL vials are filled with 5 ml of sterile-filtered 0.001% (w/v) aqueous solution of compound, and the resulting mixture is lyophilized.
  • the infusion solution is prepared by reconstituting the lyophilized compound using bacteriostatic Water- for-Injection.
  • the reaction mixture was diluted in ammonium acetate buffer (0.05M, pH 5.5 with 20% v/v methanol, 10ml) and purified using Accell CM- and QMA + Sep-Paks (Waters, Milford, MA, USA) in series.
  • the CM- and QMA + cartridges were uncoupled and the H- Me-GPE was eluted from the QMA cartridge with ammonium bicarbonate (0.3M, 6ml). The eluted material was lyophilized twice to remove the bulk of the ammonium bicarbonate, dissolved in ethanol-water (1:19, 20 ⁇ l) and aliquots stored at -70°C.
  • the optimal protocol for 3 H-Me-GPE binding was: a 10 minute preincubation in buffer (50mM Tris-HCl, pH 7.4) with protease inhibitors (20mM EDTA, ImM phenylmethylsulfonyl fluoride, 2mM N-ethylmaleimide and 5mM benzamidine), followed by a 90 minute incubation at 24 C in the same buffer including 50nM 3 H-Me-GPE, followed by 2 x 1 minute washes in ice-cold distilled water and dried in a cold air flow.
  • Non-specific binding was defined by coincubation with the unlabeled ligand (lO ⁇ M) and was typically 25-30%.
  • Tritiated GPE (Gly-[ 3 H]Pro-Glu, 1.6ml, specific activity 50-60 Ci/mmol) obtained from Sibtech, Inc., USA was used in these experiments.
  • Rats were prepared under halothane/0 2 anaesthesia. The rats were randomly assigned to one of four groups: tritiated GPE, saline + 0.1% BSA, tritiated GPE + non-tritiated GPE or tritiated proline. Rats in the tritiated GPE, tritiated proline and control groups were sacrificed at 30 min, 1 hr or 6 hrs after administration. Rats co-administered with both tritiated and non- tritiated GPE were sacrificed at 10 minutes after administration. For all groups, tissue was homogenized in Soluene ® (a tissue solubilizer; Packard Bioscience Company, Meriden CT) and counted in a ⁇ counter. IV and IP Administration
  • Rats were injected with 10 million counts of tritiated GPE in 500 ⁇ l total (made up with 0.1%) BSA in saline). Animals were sacrificed at 30 minutes, 1, 3 or 6 hrs. Tissue was homogenized in Soluene ® and counted in a ⁇ counter.
  • Rats were prepared under halothane/0 2 anaesthesia. A guide cannula was placed on the dura 7.5mm anterior from stereotaxic zero and 1.5mm from midline on the right. One million counts of GPE and 600 ⁇ l of non-tritiated GPE were injected in 8 ⁇ l total volume (made up with 0.1% BSA in saline). Rats were sacrificed 30 minutes after administration. Tissue was homogenized in Soluene ® and counted in a ⁇ counter.
  • Tritiated GPE Tritiated GPE, tritiated GPE + non-tritiated GPE, tritiated proline (Amersham) or tritiated proline + non-tritiated proline in vehicle (0.1M citrate buffer [pH6], diluted 10 times in 0.1% bovine serum albumin in 0.1M phosphate buffered saline [PBS] [pH7.3]) were then given by different routes of administration to injured and non-injured rats according to the following study design:
  • tritiated GPE tritiated GPE + non- tritiated GPE
  • tritiated proline tritiated proline + non-tritiated proline
  • Cardiac administration was performed using a syringe.
  • the syringe needle was placed into the left ventricle and one of the above four solutions was given.
  • IV administration was carried out by injecting one of the four solutions into the tail vein.
  • IP administration was performed by injecting one of the four solutions into the peritoneal cavity.
  • ICV administration was carried out according to the following procedure.
  • the rats were lightly anaesthetized again using 0.15ml SaffanTM (Pitman-Moore Ltd, NZ).
  • SaffanTM Pane-Moore Ltd, NZ
  • the infusion of one of the four solutions was made into the right lateral ventricle guided by a metal cap fitted over the rat head using a modified technique originally described by Jirikowski (J Neuroscience Methods, 42: 115-118, 1992), in order to ensure correct placement of the infusion needle.
  • Jirikowski J Neuroscience Methods, 42: 115-118, 1992
  • the rats were sacrificed using pentobarbital 10, 60 or 360 minutes after administration of either tritiated GPE or tritiated proline.
  • the distribution of administered tritiated GPE or proline was ascertained.
  • Counts/minute/mg were made in the following tissues: kidney, blood, adrenal glands, liver, lung, testicle, heart, muscle, spinal cord and brain. HPLC was used in order to check that the particles counted were either tritiated GPE or tritiated proline.
  • ICV administration GPE was found to be selectively taken up on the injured side of the brain in rats with an hypoxic-ischemic brain injury.
  • This experiment involved treating rats with a control vehicle or GPE administered peripherally 2 hours after a focal CNS injury.
  • the rats had an hypoxic-ischemic injury to one cerebral hemisphere induced in a standard manner (ligation of the carotid artery).
  • the degree and length of hypoxia, the ambient temperature and humidity were defined to standardize the degree of damage.
  • the neuronal death is restricted to the side of the carotid ligation and is primarily in the hippocampus, dentate gyrus, striatum and lateral cortex of the ligated hemisphere. There is no neuronal loss in the contralateral hemisphere.
  • the rats were transcardially perfused with 0.9%> saline followed by 4%o paraformaldehyde, and the brains were removed and embedded in paraffin.
  • Symmetric serial coronal sections (4 ⁇ m) were cut and stained with thionin/acid- fuchsin for live/dead neurons (Sirimanne et al, 1994 Journal of Neuroscience, 55: 7-14).
  • the histological outcome of neuronal survival was examined with light microscopy (Leica) in the hippocampus in the injured hald of the brain according to a reference of rat brain anatomy (Paxinos, and Watson (1982) The rat brain in stereotaxic coordinates, 2 nd Edition, Academic Press, New York, USA). Only cells with a morphology like live neurons were counted, while dead neurons or cells with morphology like glia were not included.
  • One coronal section was used for each brain.
  • a coronal section (A-P 4.5mm) was used for analysis of the hippocampus. All surviving neurons in the hippocampal CAl/2 region of the injured hemisphere were counted. Data were analysed with paired t-test and presented as mean ⁇ sem (standard error of the mean).
  • GPE analogs have application in any method of therapy or prophylaxis in which GPE has application. These include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS.
  • the ability of the GPE analogs to cross the blood brain barrier allows them to be administered peripherally to a patient in need of treatment in the brain.
  • analogs will normally be administered as part of a pharmaceutical composition or preparation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues de GPE, en particulier, des analogues de GPE capables d'induire un effet physiologique équivalent à GPE chez un patient. Ces analogues de GPE consistent en des peptides dans lesquels le Gly de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Pro, le Pro de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Gly et le Glu de Gly-Pro-Glu étant remplacé par Asn ou Asp ou Gln. Ces analogues de GPE peuvent être utilisés dans tout procédé thérapeutique ou prophylactique impliquant GPE. Ces utilisations comprennent le traitement de lésions cérébrales aiguës et de maladies neurodégénératives, y compris, sans limitation, des lésions ou des maladies du système nerveux central. On administrera normalement ces analogues de GPE dans une composition ou une préparation pharmaceutique.
EP01968959A 2000-08-24 2001-08-24 Analogues de gpe Withdrawn EP1351976A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ50653400 2000-08-24
NZ50653400 2000-08-24
PCT/US2001/041883 WO2002016408A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe

Publications (1)

Publication Number Publication Date
EP1351976A2 true EP1351976A2 (fr) 2003-10-15

Family

ID=19928066

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01968959A Withdrawn EP1351976A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe

Country Status (3)

Country Link
EP (1) EP1351976A2 (fr)
AU (1) AU2001289160A1 (fr)
WO (1) WO2002016408A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
WO2007079977A2 (fr) * 2006-01-16 2007-07-19 Dsm Ip Assets B.V. Nouvelles préparations nutraceutiques et applications
US7994127B2 (en) 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
BR112013018898B1 (pt) 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
GB201613999D0 (en) 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
WO2022055045A1 (fr) * 2020-09-08 2022-03-17 주식회사 선마린바이오테크 Dérivé peptidique ayant une activité inhibitrice de collagénase et son utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502041A1 (de) * 1985-01-23 1986-07-24 Grünenthal GmbH, 5190 Stolberg Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden
SE8803847A0 (sv) * 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
JPH09509404A (ja) * 1993-12-23 1997-09-22 オークランド ユニサービシズ リミテッド 神経アウトカムを改良するための組成物及び方法
CN1261158C (zh) * 1998-09-03 2006-06-28 诺兰兹公司 生长激素在制备用于诱导神经保护作用的药剂中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0216408A2 *

Also Published As

Publication number Publication date
WO2002016408A3 (fr) 2003-04-24
AU2001289160A1 (en) 2002-03-04
WO2002016408A2 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
US6780848B2 (en) Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease
KR100248033B1 (ko) 사이토킨 억제제
US5268164A (en) Increasing blood-brain barrier permeability with permeabilizer peptides
AU714846B2 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
KR100493830B1 (ko) 친지성부및혈관작용성장펩티드(vip)의프래그먼트의콘쥬게이트
US5482930A (en) Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
EP1351976A2 (fr) Analogues de gpe
CN118638210A (zh) 长效pth类似物的制备方法及应用
JP2004513079A (ja) 鎮痛性ペプチドを含んでなる薬剤組成物
CA2902619A1 (fr) Methodes de traitement de la sclerose en plaques
US6458357B1 (en) Retro-inverso neurotrophic and analgesic peptides
US7112570B2 (en) GPE analogs
TWI849231B (zh) 聚乙二醇化介白素-11之組合物及方法
EA007841B1 (ru) Новые пептиды - аналоги гормона высвобождения гормона роста человека
EP1372733B1 (fr) Compositions pharmaceutiques de polypeptides actifs assurant une activite pharmacologique accrue au moyen de l'administration par voie orale et parenterale
AU700838C (en) Composition and methods to improve neural outcome
CA2434831C (fr) Drogues a base de polypeptide
WO2002028412A1 (fr) Nouvelle utilisation de peptide
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
WO1996038480A1 (fr) Peptides anti-inflammatoires derives de la thrombospondine
CN120265642A (zh) 化合物及其制备方法和应用
US20020128199A1 (en) Anti-depressant effects of corticotropin release inhibiting factor
WO2002072131A1 (fr) Médicaments contre des affections hépatiques
JPH08183740A (ja) 細胞接着阻害剤及び該阻害剤を含む抗炎症剤
HK1212718B (zh) 用於减少cd36表达的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030317

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

17Q First examination report despatched

Effective date: 20080530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081010